Ultragenyx Pharmaceutical Inc. (RARE) Stock Competitors & Peer Comparison
See (RARE) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RARE | $22.83 | +5.74% | 2.2B | -3.74 | -$6.10 | N/A |
| NVO | $43.20 | +5.30% | 187.5B | 9.90 | $4.26 | +4.27% |
| VRTX | $436.09 | -1.55% | 113.1B | 26.46 | $16.85 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $603.39 | -1.30% | 63.5B | 15.03 | $40.99 | +0.59% |
| ARGX | $870.98 | -1.30% | 54.7B | 39.27 | $22.51 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $292.65 | +0.17% | 39.7B | 74.98 | $3.97 | N/A |
| RVMD | $144.70 | -2.55% | 31.8B | -21.11 | -$7.09 | N/A |
| RPRX | $54.76 | -0.18% | 23.9B | 29.28 | $1.90 | +1.64% |
Stock Comparison
RARE vs NVO Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, NVO has a market cap of 187.5B. Regarding current trading prices, RARE is priced at $22.83, while NVO trades at $43.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas NVO's P/E ratio is 9.90. In terms of profitability, RARE's ROE is +15.67%, compared to NVO's ROE of +0.66%. Regarding short-term risk, RARE is less volatile compared to NVO. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check NVO's competition here
RARE vs VRTX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, VRTX has a market cap of 113.1B. Regarding current trading prices, RARE is priced at $22.83, while VRTX trades at $436.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas VRTX's P/E ratio is 26.46. In terms of profitability, RARE's ROE is +15.67%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, RARE is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check VRTX's competition here
RARE vs VRNA Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, RARE is priced at $22.83, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas VRNA's P/E ratio is -102.80. In terms of profitability, RARE's ROE is +15.67%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, RARE is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check VRNA's competition here
RARE vs REGN Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, REGN has a market cap of 63.5B. Regarding current trading prices, RARE is priced at $22.83, while REGN trades at $603.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas REGN's P/E ratio is 15.03. In terms of profitability, RARE's ROE is +15.67%, compared to REGN's ROE of +0.14%. Regarding short-term risk, RARE is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check REGN's competition here
RARE vs ARGX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, ARGX has a market cap of 54.7B. Regarding current trading prices, RARE is priced at $22.83, while ARGX trades at $870.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas ARGX's P/E ratio is 39.27. In terms of profitability, RARE's ROE is +15.67%, compared to ARGX's ROE of +0.37%. Regarding short-term risk, RARE is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check ARGX's competition here
RARE vs SGEN Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, RARE is priced at $22.83, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas SGEN's P/E ratio is -57.19. In terms of profitability, RARE's ROE is +15.67%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, RARE is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check SGEN's competition here
RARE vs ALNY Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, ALNY has a market cap of 39.7B. Regarding current trading prices, RARE is priced at $22.83, while ALNY trades at $292.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas ALNY's P/E ratio is 74.98. In terms of profitability, RARE's ROE is +15.67%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, RARE is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check ALNY's competition here
RARE vs RVMD Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, RVMD has a market cap of 31.8B. Regarding current trading prices, RARE is priced at $22.83, while RVMD trades at $144.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas RVMD's P/E ratio is -21.11. In terms of profitability, RARE's ROE is +15.67%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, RARE is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check RVMD's competition here
RARE vs RPRX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, RPRX has a market cap of 23.9B. Regarding current trading prices, RARE is priced at $22.83, while RPRX trades at $54.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas RPRX's P/E ratio is 29.28. In terms of profitability, RARE's ROE is +15.67%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, RARE is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check RPRX's competition here
RARE vs UTHR Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, UTHR has a market cap of 23.5B. Regarding current trading prices, RARE is priced at $22.83, while UTHR trades at $543.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas UTHR's P/E ratio is 20.45. In terms of profitability, RARE's ROE is +15.67%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, RARE is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check UTHR's competition here
RARE vs BNTX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, BNTX has a market cap of 21.9B. Regarding current trading prices, RARE is priced at $22.83, while BNTX trades at $86.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas BNTX's P/E ratio is -14.71. In terms of profitability, RARE's ROE is +15.67%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, RARE is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check BNTX's competition here
RARE vs INSM Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, INSM has a market cap of 21.5B. Regarding current trading prices, RARE is priced at $22.83, while INSM trades at $92.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas INSM's P/E ratio is -17.19. In terms of profitability, RARE's ROE is +15.67%, compared to INSM's ROE of -1.30%. Regarding short-term risk, RARE is less volatile compared to INSM. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check INSM's competition here
RARE vs ROIV Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, ROIV has a market cap of 20.9B. Regarding current trading prices, RARE is priced at $22.83, while ROIV trades at $28.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas ROIV's P/E ratio is -53.80. In terms of profitability, RARE's ROE is +15.67%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, RARE is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check ROIV's competition here
RARE vs INCY Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, INCY has a market cap of 20.6B. Regarding current trading prices, RARE is priced at $22.83, while INCY trades at $105.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas INCY's P/E ratio is 14.58. In terms of profitability, RARE's ROE is +15.67%, compared to INCY's ROE of +0.29%. Regarding short-term risk, RARE is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check INCY's competition here
RARE vs BGNE Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, RARE is priced at $22.83, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas BGNE's P/E ratio is -22.55. In terms of profitability, RARE's ROE is +15.67%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, RARE is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check BGNE's competition here
RARE vs MRNA Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, MRNA has a market cap of 18.9B. Regarding current trading prices, RARE is priced at $22.83, while MRNA trades at $46.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas MRNA's P/E ratio is -5.86. In terms of profitability, RARE's ROE is +15.67%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, RARE is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check MRNA's competition here
RARE vs DNA-WT Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, RARE is priced at $22.83, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, RARE's ROE is +15.67%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, RARE is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check DNA-WT's competition here
RARE vs NBIX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, NBIX has a market cap of 16.6B. Regarding current trading prices, RARE is priced at $22.83, while NBIX trades at $163.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas NBIX's P/E ratio is 25.37. In terms of profitability, RARE's ROE is +15.67%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, RARE is less volatile compared to NBIX. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check NBIX's competition here
RARE vs GMAB Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, GMAB has a market cap of 15.4B. Regarding current trading prices, RARE is priced at $22.83, while GMAB trades at $24.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas GMAB's P/E ratio is 19.02. In terms of profitability, RARE's ROE is +15.67%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, RARE is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check GMAB's competition here
RARE vs JAZZ Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, JAZZ has a market cap of 14.4B. Regarding current trading prices, RARE is priced at $22.83, while JAZZ trades at $228.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas JAZZ's P/E ratio is 1909.92. In terms of profitability, RARE's ROE is +15.67%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, RARE is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check JAZZ's competition here
RARE vs EXEL Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, EXEL has a market cap of 13.3B. Regarding current trading prices, RARE is priced at $22.83, while EXEL trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas EXEL's P/E ratio is 17.55. In terms of profitability, RARE's ROE is +15.67%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, RARE is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check EXEL's competition here
RARE vs BBIO Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, BBIO has a market cap of 13.3B. Regarding current trading prices, RARE is priced at $22.83, while BBIO trades at $67.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas BBIO's P/E ratio is -18.10. In terms of profitability, RARE's ROE is +15.67%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, RARE is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check BBIO's competition here
RARE vs ASND Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, ASND has a market cap of 13.2B. Regarding current trading prices, RARE is priced at $22.83, while ASND trades at $209.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas ASND's P/E ratio is 24.45. In terms of profitability, RARE's ROE is +15.67%, compared to ASND's ROE of -56.42%. Regarding short-term risk, RARE is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check ASND's competition here
RARE vs AXSM Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, AXSM has a market cap of 12.6B. Regarding current trading prices, RARE is priced at $22.83, while AXSM trades at $247.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas AXSM's P/E ratio is -66.03. In terms of profitability, RARE's ROE is +15.67%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, RARE is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check AXSM's competition here
RARE vs KRTX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, RARE is priced at $22.83, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas KRTX's P/E ratio is -28.09. In terms of profitability, RARE's ROE is +15.67%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, RARE is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check KRTX's competition here
RARE vs IONS Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, IONS has a market cap of 12.3B. Regarding current trading prices, RARE is priced at $22.83, while IONS trades at $73.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas IONS's P/E ratio is -37.10. In terms of profitability, RARE's ROE is +15.67%, compared to IONS's ROE of -0.59%. Regarding short-term risk, RARE is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check IONS's competition here
RARE vs RNAM Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, RARE is priced at $22.83, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas RNAM's P/E ratio is -17.39. In terms of profitability, RARE's ROE is +15.67%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, RARE is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check RNAM's competition here
RARE vs BMRN Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, BMRN has a market cap of 11.2B. Regarding current trading prices, RARE is priced at $22.83, while BMRN trades at $56.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas BMRN's P/E ratio is 41.66. In terms of profitability, RARE's ROE is +15.67%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, RARE is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check BMRN's competition here
RARE vs SMMT Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, SMMT has a market cap of 11.1B. Regarding current trading prices, RARE is priced at $22.83, while SMMT trades at $12.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas SMMT's P/E ratio is -8.99. In terms of profitability, RARE's ROE is +15.67%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, RARE is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check SMMT's competition here
RARE vs MDGL Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, MDGL has a market cap of 11B. Regarding current trading prices, RARE is priced at $22.83, while MDGL trades at $480.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas MDGL's P/E ratio is -35.33. In terms of profitability, RARE's ROE is +15.67%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, RARE is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check MDGL's competition here
RARE vs ARWR Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, ARWR has a market cap of 10.3B. Regarding current trading prices, RARE is priced at $22.83, while ARWR trades at $70.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas ARWR's P/E ratio is -32.30. In terms of profitability, RARE's ROE is +15.67%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, RARE is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check ARWR's competition here
RARE vs RXDX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, RARE is priced at $22.83, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas RXDX's P/E ratio is -56.47. In terms of profitability, RARE's ROE is +15.67%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, RARE is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check RXDX's competition here
RARE vs KRYS Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, KRYS has a market cap of 9.1B. Regarding current trading prices, RARE is priced at $22.83, while KRYS trades at $311.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas KRYS's P/E ratio is 41.41. In terms of profitability, RARE's ROE is +15.67%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, RARE is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check KRYS's competition here
RARE vs NUVL Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, RARE is priced at $22.83, while NUVL trades at $123.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas NUVL's P/E ratio is -20.34. In terms of profitability, RARE's ROE is +15.67%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, RARE is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check NUVL's competition here
RARE vs IMGN Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, RARE is priced at $22.83, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas IMGN's P/E ratio is -111.55. In terms of profitability, RARE's ROE is +15.67%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, RARE is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check IMGN's competition here
RARE vs TECH Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, TECH has a market cap of 8.5B. Regarding current trading prices, RARE is priced at $22.83, while TECH trades at $52.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas TECH's P/E ratio is 77.73. In terms of profitability, RARE's ROE is +15.67%, compared to TECH's ROE of +0.05%. Regarding short-term risk, RARE is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check TECH's competition here
RARE vs CYTK Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, CYTK has a market cap of 8.5B. Regarding current trading prices, RARE is priced at $22.83, while CYTK trades at $67.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas CYTK's P/E ratio is -9.99. In terms of profitability, RARE's ROE is +15.67%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, RARE is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check CYTK's competition here
RARE vs HALO Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, HALO has a market cap of 8.5B. Regarding current trading prices, RARE is priced at $22.83, while HALO trades at $70.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas HALO's P/E ratio is 25.08. In terms of profitability, RARE's ROE is +15.67%, compared to HALO's ROE of +1.26%. Regarding short-term risk, RARE is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check HALO's competition here
RARE vs BPMC Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, RARE is priced at $22.83, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas BPMC's P/E ratio is -51.58. In terms of profitability, RARE's ROE is +15.67%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, RARE is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check BPMC's competition here
RARE vs CORT Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, CORT has a market cap of 8.3B. Regarding current trading prices, RARE is priced at $22.83, while CORT trades at $78.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas CORT's P/E ratio is 221.40. In terms of profitability, RARE's ROE is +15.67%, compared to CORT's ROE of +0.08%. Regarding short-term risk, RARE is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check CORT's competition here
RARE vs CERE Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, RARE is priced at $22.83, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas CERE's P/E ratio is -16.47. In terms of profitability, RARE's ROE is +15.67%, compared to CERE's ROE of -0.72%. Regarding short-term risk, RARE is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check CERE's competition here
RARE vs IBRX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, IBRX has a market cap of 7.6B. Regarding current trading prices, RARE is priced at $22.83, while IBRX trades at $7.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas IBRX's P/E ratio is -8.24. In terms of profitability, RARE's ROE is +15.67%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, RARE is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check IBRX's competition here
RARE vs MTSR Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, RARE is priced at $22.83, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas MTSR's P/E ratio is -23.58. In terms of profitability, RARE's ROE is +15.67%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, RARE is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check MTSR's competition here
RARE vs ALKS Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, ALKS has a market cap of 7.4B. Regarding current trading prices, RARE is priced at $22.83, while ALKS trades at $44.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas ALKS's P/E ratio is 49.21. In terms of profitability, RARE's ROE is +15.67%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, RARE is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check ALKS's competition here
RARE vs MRUS Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, RARE is priced at $22.83, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas MRUS's P/E ratio is -17.05. In terms of profitability, RARE's ROE is +15.67%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, RARE is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check MRUS's competition here
RARE vs PTGX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, PTGX has a market cap of 6.8B. Regarding current trading prices, RARE is priced at $22.83, while PTGX trades at $107.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas PTGX's P/E ratio is -58.49. In terms of profitability, RARE's ROE is +15.67%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, RARE is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check PTGX's competition here
RARE vs PCVX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, PCVX has a market cap of 6.8B. Regarding current trading prices, RARE is priced at $22.83, while PCVX trades at $45.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas PCVX's P/E ratio is -6.96. In terms of profitability, RARE's ROE is +15.67%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, RARE is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check PCVX's competition here
RARE vs ABVX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, ABVX has a market cap of 6.7B. Regarding current trading prices, RARE is priced at $22.83, while ABVX trades at $98.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas ABVX's P/E ratio is -19.16. In terms of profitability, RARE's ROE is +15.67%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, RARE is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check ABVX's competition here
RARE vs ACLX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, RARE is priced at $22.83, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas ACLX's P/E ratio is -28.27. In terms of profitability, RARE's ROE is +15.67%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, RARE is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check ACLX's competition here
RARE vs TGTX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, TGTX has a market cap of 6.6B. Regarding current trading prices, RARE is priced at $22.83, while TGTX trades at $47.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas TGTX's P/E ratio is 15.16. In terms of profitability, RARE's ROE is +15.67%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, RARE is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check TGTX's competition here
RARE vs RETA Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, RARE is priced at $22.83, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas RETA's P/E ratio is -66.29. In terms of profitability, RARE's ROE is +15.67%, compared to RETA's ROE of +0.47%. Regarding short-term risk, RARE is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check RETA's competition here
RARE vs IMVT Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, IMVT has a market cap of 6.5B. Regarding current trading prices, RARE is priced at $22.83, while IMVT trades at $31.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas IMVT's P/E ratio is -11.41. In terms of profitability, RARE's ROE is +15.67%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, RARE is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check IMVT's competition here
RARE vs KYMR Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, KYMR has a market cap of 6.3B. Regarding current trading prices, RARE is priced at $22.83, while KYMR trades at $78.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas KYMR's P/E ratio is -21.48. In terms of profitability, RARE's ROE is +15.67%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, RARE is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check KYMR's competition here
RARE vs LEGN Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, LEGN has a market cap of 6.2B. Regarding current trading prices, RARE is priced at $22.83, while LEGN trades at $34.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas LEGN's P/E ratio is -24.27. In terms of profitability, RARE's ROE is +15.67%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, RARE is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check LEGN's competition here
RARE vs CNTA Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, CNTA has a market cap of 6.2B. Regarding current trading prices, RARE is priced at $22.83, while CNTA trades at $39.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas CNTA's P/E ratio is -22.34. In terms of profitability, RARE's ROE is +15.67%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, RARE is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check CNTA's competition here
RARE vs PTCT Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, PTCT has a market cap of 6.1B. Regarding current trading prices, RARE is priced at $22.83, while PTCT trades at $73.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas PTCT's P/E ratio is -29.01. In terms of profitability, RARE's ROE is +15.67%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, RARE is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check PTCT's competition here
RARE vs RYTM Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, RYTM has a market cap of 6B. Regarding current trading prices, RARE is priced at $22.83, while RYTM trades at $86.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas RYTM's P/E ratio is -28.07. In terms of profitability, RARE's ROE is +15.67%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, RARE is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check RYTM's competition here
RARE vs LQDA Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, LQDA has a market cap of 5.7B. Regarding current trading prices, RARE is priced at $22.83, while LQDA trades at $65.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas LQDA's P/E ratio is 376.53. In terms of profitability, RARE's ROE is +15.67%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, RARE is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check LQDA's competition here
RARE vs BLTE Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, BLTE has a market cap of 5.7B. Regarding current trading prices, RARE is priced at $22.83, while BLTE trades at $139.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas BLTE's P/E ratio is -55.68. In terms of profitability, RARE's ROE is +15.67%, compared to BLTE's ROE of -0.27%. Regarding short-term risk, RARE is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check BLTE's competition here
RARE vs CDTX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, RARE is priced at $22.83, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas CDTX's P/E ratio is -19.77. In terms of profitability, RARE's ROE is +15.67%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, RARE is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check CDTX's competition here
RARE vs ABCM Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, RARE is priced at $22.83, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, RARE's ROE is +15.67%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, RARE is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check ABCM's competition here
RARE vs ISEE Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, RARE is priced at $22.83, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas ISEE's P/E ratio is -22.44. In terms of profitability, RARE's ROE is +15.67%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, RARE is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check ISEE's competition here
RARE vs COGT Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, COGT has a market cap of 5.5B. Regarding current trading prices, RARE is priced at $22.83, while COGT trades at $31.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas COGT's P/E ratio is -14.74. In terms of profitability, RARE's ROE is +15.67%, compared to COGT's ROE of -0.83%. Regarding short-term risk, RARE is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check COGT's competition here
RARE vs SRRK Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, SRRK has a market cap of 5.5B. Regarding current trading prices, RARE is priced at $22.83, while SRRK trades at $45.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas SRRK's P/E ratio is -13.21. In terms of profitability, RARE's ROE is +15.67%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, RARE is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check SRRK's competition here
RARE vs PRAX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, PRAX has a market cap of 5.3B. Regarding current trading prices, RARE is priced at $22.83, while PRAX trades at $243.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas PRAX's P/E ratio is -18.70. In terms of profitability, RARE's ROE is +15.67%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, RARE is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check PRAX's competition here
RARE vs APGE Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, APGE has a market cap of 5.3B. Regarding current trading prices, RARE is priced at $22.83, while APGE trades at $82.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas APGE's P/E ratio is -19.63. In terms of profitability, RARE's ROE is +15.67%, compared to APGE's ROE of -0.33%. Regarding short-term risk, RARE is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check APGE's competition here
RARE vs FBIOX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, FBIOX has a market cap of 5.3B. Regarding current trading prices, RARE is priced at $22.83, while FBIOX trades at $24.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas FBIOX's P/E ratio is N/A. In terms of profitability, RARE's ROE is +15.67%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, RARE is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check FBIOX's competition here
RARE vs APLS Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, RARE is priced at $22.83, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas APLS's P/E ratio is 38.35. In terms of profitability, RARE's ROE is +15.67%, compared to APLS's ROE of +0.40%. Regarding short-term risk, RARE is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check APLS's competition here
RARE vs CGON Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, CGON has a market cap of 5B. Regarding current trading prices, RARE is priced at $22.83, while CGON trades at $54.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas CGON's P/E ratio is -24.22. In terms of profitability, RARE's ROE is +15.67%, compared to CGON's ROE of -0.23%. Regarding short-term risk, RARE is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check CGON's competition here
RARE vs CRSP Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, CRSP has a market cap of 5B. Regarding current trading prices, RARE is priced at $22.83, while CRSP trades at $49.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas CRSP's P/E ratio is -8.34. In terms of profitability, RARE's ROE is +15.67%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, RARE is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check CRSP's competition here
RARE vs LGND Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, LGND has a market cap of 4.9B. Regarding current trading prices, RARE is priced at $22.83, while LGND trades at $247.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas LGND's P/E ratio is 31.68. In terms of profitability, RARE's ROE is +15.67%, compared to LGND's ROE of +0.16%. Regarding short-term risk, RARE is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check LGND's competition here
RARE vs CAI Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, CAI has a market cap of 4.8B. Regarding current trading prices, RARE is priced at $22.83, while CAI trades at $17.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas CAI's P/E ratio is -6.14. In terms of profitability, RARE's ROE is +15.67%, compared to CAI's ROE of +0.06%. Regarding short-term risk, RARE is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check CAI's competition here
RARE vs MIRM Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, MIRM has a market cap of 4.8B. Regarding current trading prices, RARE is priced at $22.83, while MIRM trades at $94.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas MIRM's P/E ratio is -7.02. In terms of profitability, RARE's ROE is +15.67%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, RARE is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check MIRM's competition here
RARE vs TERN Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, RARE is priced at $22.83, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas TERN's P/E ratio is -51.41. In terms of profitability, RARE's ROE is +15.67%, compared to TERN's ROE of -0.20%. Regarding short-term risk, RARE is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check TERN's competition here
RARE vs SYRE Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, SYRE has a market cap of 4.6B. Regarding current trading prices, RARE is priced at $22.83, while SYRE trades at $75.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas SYRE's P/E ratio is -36.06. In terms of profitability, RARE's ROE is +15.67%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, RARE is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check SYRE's competition here
RARE vs FOLD Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, RARE is priced at $22.83, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas FOLD's P/E ratio is -161.00. In terms of profitability, RARE's ROE is +15.67%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, RARE is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check FOLD's competition here
RARE vs TVTX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, TVTX has a market cap of 4.5B. Regarding current trading prices, RARE is priced at $22.83, while TVTX trades at $47.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas TVTX's P/E ratio is -97.14. In terms of profitability, RARE's ROE is +15.67%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, RARE is less volatile compared to TVTX. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check TVTX's competition here
RARE vs CELC Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, CELC has a market cap of 4.5B. Regarding current trading prices, RARE is priced at $22.83, while CELC trades at $89.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas CELC's P/E ratio is -23.74. In terms of profitability, RARE's ROE is +15.67%, compared to CELC's ROE of -2.45%. Regarding short-term risk, RARE is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check CELC's competition here
RARE vs AKRO Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, RARE is priced at $22.83, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas AKRO's P/E ratio is -14.57. In terms of profitability, RARE's ROE is +15.67%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, RARE is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check AKRO's competition here
RARE vs ALPN Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, RARE is priced at $22.83, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas ALPN's P/E ratio is -101.52. In terms of profitability, RARE's ROE is +15.67%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, RARE is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check ALPN's competition here
RARE vs OPT Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, RARE is priced at $22.83, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas OPT's P/E ratio is -1.52. In terms of profitability, RARE's ROE is +15.67%, compared to OPT's ROE of +1.09%. Regarding short-term risk, RARE is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check OPT's competition here
RARE vs ERAS Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, ERAS has a market cap of 4.2B. Regarding current trading prices, RARE is priced at $22.83, while ERAS trades at $13.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas ERAS's P/E ratio is -14.42. In terms of profitability, RARE's ROE is +15.67%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, RARE is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check ERAS's competition here
RARE vs XENE Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, XENE has a market cap of 4.2B. Regarding current trading prices, RARE is priced at $22.83, while XENE trades at $51.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas XENE's P/E ratio is -11.23. In terms of profitability, RARE's ROE is +15.67%, compared to XENE's ROE of -0.49%. Regarding short-term risk, RARE is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check XENE's competition here
RARE vs MRTX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, RARE is priced at $22.83, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas MRTX's P/E ratio is -4.82. In terms of profitability, RARE's ROE is +15.67%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, RARE is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check MRTX's competition here
RARE vs MANE Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, MANE has a market cap of 4B. Regarding current trading prices, RARE is priced at $22.83, while MANE trades at $93.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas MANE's P/E ratio is -36.10. In terms of profitability, RARE's ROE is +15.67%, compared to MANE's ROE of -0.95%. Regarding short-term risk, RARE is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check MANE's competition here
RARE vs VCYT Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, VCYT has a market cap of 3.9B. Regarding current trading prices, RARE is priced at $22.83, while VCYT trades at $48.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas VCYT's P/E ratio is 45.59. In terms of profitability, RARE's ROE is +15.67%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, RARE is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check VCYT's competition here
RARE vs CPRX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, RARE is priced at $22.83, while CPRX trades at $31.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas CPRX's P/E ratio is 18.12. In terms of profitability, RARE's ROE is +15.67%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, RARE is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check CPRX's competition here
RARE vs RYZB Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, RARE is priced at $22.83, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas RYZB's P/E ratio is -57.86. In terms of profitability, RARE's ROE is +15.67%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, RARE is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check RYZB's competition here
RARE vs ACAD Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, RARE is priced at $22.83, while ACAD trades at $21.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas ACAD's P/E ratio is 9.88. In terms of profitability, RARE's ROE is +15.67%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, RARE is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check ACAD's competition here
RARE vs CBAY Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, RARE is priced at $22.83, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas CBAY's P/E ratio is -32.81. In terms of profitability, RARE's ROE is +15.67%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, RARE is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check CBAY's competition here
RARE vs CRNX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, CRNX has a market cap of 3.7B. Regarding current trading prices, RARE is priced at $22.83, while CRNX trades at $34.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas CRNX's P/E ratio is -6.80. In terms of profitability, RARE's ROE is +15.67%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, RARE is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check CRNX's competition here
RARE vs TNGX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, TNGX has a market cap of 3.7B. Regarding current trading prices, RARE is priced at $22.83, while TNGX trades at $29.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas TNGX's P/E ratio is -38.02. In terms of profitability, RARE's ROE is +15.67%, compared to TNGX's ROE of -0.42%. Regarding short-term risk, RARE is less volatile compared to TNGX. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check TNGX's competition here
RARE vs EWTX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, EWTX has a market cap of 3.7B. Regarding current trading prices, RARE is priced at $22.83, while EWTX trades at $33.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas EWTX's P/E ratio is -20.52. In terms of profitability, RARE's ROE is +15.67%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, RARE is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check EWTX's competition here
RARE vs KNSA Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, KNSA has a market cap of 3.7B. Regarding current trading prices, RARE is priced at $22.83, while KNSA trades at $49.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas KNSA's P/E ratio is 53.52. In terms of profitability, RARE's ROE is +15.67%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, RARE is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check KNSA's competition here
RARE vs NAMS Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, NAMS has a market cap of 3.6B. Regarding current trading prices, RARE is priced at $22.83, while NAMS trades at $29.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas NAMS's P/E ratio is -17.07. In terms of profitability, RARE's ROE is +15.67%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, RARE is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check NAMS's competition here
RARE vs SWTX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, RARE is priced at $22.83, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas SWTX's P/E ratio is -13.78. In terms of profitability, RARE's ROE is +15.67%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, RARE is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.Check SWTX's competition here
RARE vs DNTH Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, DNTH has a market cap of 3.5B. Regarding current trading prices, RARE is priced at $22.83, while DNTH trades at $76.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas DNTH's P/E ratio is -19.99. In terms of profitability, RARE's ROE is +15.67%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, RARE is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check DNTH's competition here
RARE vs VKTX Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, VKTX has a market cap of 3.4B. Regarding current trading prices, RARE is priced at $22.83, while VKTX trades at $27.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas VKTX's P/E ratio is -7.04. In terms of profitability, RARE's ROE is +15.67%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, RARE is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check VKTX's competition here
RARE vs DNLI Comparison June 2026
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 2.2B. In comparison, DNLI has a market cap of 3.3B. Regarding current trading prices, RARE is priced at $22.83, while DNLI trades at $20.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -3.74, whereas DNLI's P/E ratio is -7.22. In terms of profitability, RARE's ROE is +15.67%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, RARE is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.Check DNLI's competition here